Scarica l'app Stockscreener
321.19
0.43%
1.36
Precedente Chiudi:
$319.83
Aprire:
$323.05
Volume 24 ore:
246.57K
Relative Volume:
0.60
Capitalizzazione di mercato:
$12.63B
Reddito:
$1.45B
Utile/perdita netta:
$171.05M
Rapporto P/E:
73.91
EPS:
4.3459
Flusso di cassa netto:
$212.73M
1 W Prestazione:
+0.77%
1M Prestazione:
+1.72%
6M Prestazione:
-10.32%
1 anno Prestazione:
+27.32%
Intervallo 1D:
$318.70
$323.05
Intervallo di 1 settimana:
$317.09
$323.05
Portata 52W:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Nome
Penumbra Inc
Settore
Industria
Telefono
(510) 995-2486
Indirizzo
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
321.19 | 12.57B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-11-18 | Iniziato | Wells Fargo | Underweight |
| 2025-10-08 | Aggiornamento | Needham | Hold → Buy |
| 2025-09-02 | Iniziato | Evercore ISI | Outperform |
| 2025-03-14 | Iniziato | BofA Securities | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-12-17 | Iniziato | Oppenheimer | Outperform |
| 2024-12-11 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Iniziato | Stifel | Buy |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-31 | Downgrade | Citigroup | Buy → Neutral |
| 2024-07-31 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-29 | Downgrade | Needham | Buy → Hold |
| 2023-01-30 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-10-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-09-09 | Aggiornamento | Needham | Hold → Buy |
| 2022-07-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-04-19 | Iniziato | Deutsche Bank | Buy |
| 2022-03-08 | Iniziato | Needham | Hold |
| 2021-09-16 | Iniziato | Truist | Buy |
| 2021-06-04 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-12-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-10-07 | Ripresa | Canaccord Genuity | Buy |
| 2020-09-29 | Iniziato | BTIG Research | Buy |
| 2020-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-05-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Iniziato | William Blair | Outperform |
| 2018-10-29 | Ripresa | BofA/Merrill | Buy |
| 2018-10-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-02-21 | Iniziato | William Blair | Outperform |
| 2018-01-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Reiterato | Canaccord Genuity | Buy |
| 2015-10-13 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Penumbra Inc Borsa (PEN) Ultime notizie
Penumbra Releases Results of CAVT System Study for Stroke Patients - dicardiology.com
Penumbra Inc (PEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Penumbra Inc (PEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Penumbra Inc (PEN) Income Statement - TradingKey
Penumbra Inc (PEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Penumbra Inc (PEN) Cash Flow - TradingKey
Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
PEN|Penumbra Inc|Price:318.730|Chg%:+0.760 - TradingKey
Penumbra Market Sentiment - Benzinga España
WHITEBOX ADVISORS LLC's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Australia
Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued - Yahoo Finance
Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study - Yahoo Finance
Penumbra, Inc. Revenue Breakdown – BMV:PEN - TradingView
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Magnendo Corp. announced that it has received $18 million in funding from Penumbra, Inc. and other investors - marketscreener.com
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention - The Manila Times
Penumbra Inc (PEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Penumbra stock reflects growth ambitions amid recent revenue gains - Ad-hoc-news.de
SA JPMorgan Mid-Cap Growth Portfolio's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins - Sahm
Morningstar Alternatives Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra’s Thunderbolt stroke device meets study goals By Investing.com - Investing.com South Africa
Penumbra reports THUNDER study results for THUNDERBOLT stroke device - Bitget
Penumbra (PEN) Reports Promising Results for THUNDERBOLT Thrombe - GuruFocus
Penumbra’s Thunderbolt stroke device meets study goals - Investing.com
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care - AOL.com
ETFs Investing in Penumbra, Inc. Stocks - TradingView
PEN stock trades steady as Penumbra focuses on growth after recent quarter - Ad-hoc-news.de
Penumbra, Inc. (PEN) Stock forecasts - Yahoo Finance UK
3 Medical Device Stocks Giving Investors a Different Healthcare Play - MarketBeat
Penumbra’s FORWARD Real‑World Stroke Study Might Change The Case For Investing In Penumbra (PEN) - Sahm
Penumbra Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterMargin Guidance - dars.gov.et
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Penumbra (PEN) Starts The FORWARD Study, Is The Stock Already Expensive? - Sahm
Risk of Antitrust Challenges Remains Low for Boston's Acquisition of Penumbra - Morningstar
Penumbra Inc. (PEN) Q1 2026 Earnings: EPS Misses Estimates by 24.49%, Stock Inches UpCore Business Growth - dars.gov.et
Thunderbolt Computer-Assisted Vacuum Thrombectomy (CAVT) Platform, US - Medical Device Network
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS) - The Globe and Mail
Penumbra (PEN) Stock Forum and Discussion - Moomoo
(PEN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price to earnings forward of Penumbra, Inc. – MUN:0P8 - TradingView
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - AOL.com
Enterprise value to EBITDA forward of Penumbra, Inc. – NYSE:PEN - TradingView
Penumbra Deadline Alert - TMX Newsfile
Penumbra starts trial of clot removal device in stroke subgroup - MedTech Dive
Penumbra Inc. (PEN) Holds Steady Near $317 as Traders Eye Key ResistanceAAII Bearish - DonanımHaber
What Is Driving Penumbra (NYSE:PEN) on the NYSE Composite? - Kalkine Media
Penumbra enrolls first patient in distal acute stroke thrombectomy study - MassDevice
Penumbra initiates study on stroke treatment for distal occlusions - Investing.com
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke - BioSpace
Penumbra Inc Azioni (PEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
11.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):